Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

The IPIX/U.S. Gov't Brilacidin Collaboration began 2.5 yrs Ago
and is a BIG part of Leo's strategy for Brilacidin's antiviral development.

February 18, 2020
Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment

As to Brilacidin’s antiviral properties, the strategy is to explore research collaborations and federal grant opportunities to further evaluate the drug’s potential to treat Coronaviruses without tapping into resources dedicated for clinical research in Brilacidin’s primary indications.

http://www.ipharminc.com/press-release/2020/2/18/innovation-pharmaceuticals-exploring-lead-defensin-mimetic-drug-candidate-brilacidin-as-potential-novel-coronavirus-treatment

February 24, 2020
Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus (COVID-19)

Should laboratory tests support Brilacidin’s antiviral activity against SARS-CoV-2 (COVID-19), and potentially other RNA viruses, the Company will look to expedite research and clinical development of Brilacidin as a potential antiviral therapy via pharmaceutical partnerships, academic collaborations and government grants.

http://www.ipharminc.com/press-release/2020/2/24/innovation-pharmaceuticals-submits-material-transfer-agreement-to-study-lead-defensin-mimetic-brilacidin-for-coronavirus-covid-19

February 27, 2020
Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19

Under terms of the agreement, scientific research partners at the RBL plan to evaluate Brilacidin’s potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the virus responsible for COVID-19. Mechanism of action studies of Brilacidin, along with assessing possible synergistic effects with other antivirals, are also planned. It is anticipated these tests might be completed within several weeks of the RBL’s receipt of Brilacidin.

http://www.ipharminc.com/press-release/2020/2/27/innovation-pharmaceuticals-to-ship-brilacidin-to-us-regional-biocontainment-laboratory-for-research-against-coronavirus-covid-19

March 6, 2020
Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus COVID-19 Treatment

Today, the Company announces that a second MTA has been signed to ship Brilacidin to a major U.S. university for analysis. One of world’s leading coronavirus experts is overseeing the research. Innovation management is awaiting approval from the university to disclose additional details on the agreement and hopes to further inform shareholders next week regarding this development.

http://www.ipharminc.com/press-release/2020/3/6/innovation-pharmaceuticals-signs-second-mta-to-explore-brilacidin-as-coronavirus-covid-19-treatment

October 30, 2020
Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results Demonstrating Brilacidin’s COVID-19 Treatment Potential

During the global COVID-19 pandemic, we selectively formed new external industry partnerships, including this opportunity to research a drug candidate like Brilacidin,” said Aarthi Narayanan, PhD, Associate Professor of Systems Biology in Mason’s College of Science. “In testing at GMU’s BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic.

http://www.ipharminc.com/press-release/2020/10/30/innovation-pharmaceuticals-and-george-mason-university-announce-public-release-of-laboratory-testing-results-demonstrating-brilacidins-covid-19-treatment-potential

June 23, 2022
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers

Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication.

http://www.ipharminc.com/press-release/2022/6/23/innovation-pharmaceuticals-reports-brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers

June 28, 2022
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.

http://www.ipharminc.com/press-release/2022/6/28/innovation-pharmaceuticals-announces-new-antiviral-research-on-brilacidin-in-bunyaviruses-and-alphaviruses-to-be-presented-at-the-2022-military-health-system-research-symposium

August 5, 2022
Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin’s Treatment Potential Against Monkeypox

Testing in poxviruses builds on earlier NIH/NIAID-affiliated research of Brilacidin in other acutely infectious virus families, including coronaviruses, alphaviruses, flaviviruses, and filoviruses, with a corresponding scientific paper being prepared for publication.

http://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox

The U.S. Government (NIH/NIAIN/FDA, etc) and it's funded research entities are well aware of Brilacidin's broad-range inhibiting effect on various families of viruses. The government's immediate priorities are COVID and Monkeypox and, testing this seemingly broad-spectrum antiviral prospect, Btilacidin, against them would seem to be a no- brainer.

The misconception, as williamssc alluded, is interpreting a drug's clinical failure as the drug having no value in the therapeutic process. Remdesivir is an obvious example of a drug, that failed its clinical test only to find a role in the COVID therapeutic process. Likewise, Brilacidin also failed its "late-disease-stage" COVID clinical trial and the NIH/NIAID/George Mason/Rutgers, etc remain as interested as ever in Brilacidin. The evidence suggest Brilacidin's best COVID role is probably prophylaxis.

The government remains interested in Brilacidin because of what the data suggest about this drug and how it can help the U.S, government deal with the current pandemic and public health emergency, and future ones as well.

I find it interesting that when the last two deadly and troublesome viruses (C-19/Mkp) began to take root in America highly-qualified scientists and researchers/academics knew enough about Brilacidin to think it deserved a "shot."

The U.S. government is, essentially, in control of IPIX's Brilacidin Antiviral Program and that's O.K. since they are "Paying The Cost To Be The Boss." Over the past 2.5 years, the cost of lab testing, clinical trial has to be in the millions.

The U.S. government is aware that Brilacidin has value and, as the Monkeypox testing of Brilacidin show, plan to unlock (or cause to be unlocked) and use that value consistent with its disease-fighting responsibility. This should mean many million$ for IPIX.

B will get many more "chances" because the U.S. gov't paid for "...all this new positive anti-viral evidence that has come to light."

Message in reply to:
Remdesiver failed it's first clinical trial miserably but yet went on to be a standard of care for covid-19. B needs another chance especially with all this new positive anti-viral evidence that has come to light.